NRLiSt BDB, the manually curated nuclear receptors ligands and structures benchmarking database.

Nuclear receptors (NRs) constitute an important class of drug targets. We created the most exhaustive NR-focused benchmarking database to date, the NRLiSt BDB (NRs ligands and structures benchmarking database). The 9905 compounds and 339 structures of the NRLiSt BDB are ready for structure-based and ligand-based virtual screening. In the present study, we detail the protocol used to generate the NRLiSt BDB and its features. We also give some examples of the errors that we found in ChEMBL that convinced us to manually review all original papers. Since extensive and manually curated experimental data about NR ligands and structures are provided in the NRLiSt BDB, it should become a powerful tool to assess the performance of virtual screening methods on NRs, to assist the understanding of NR's function and modulation, and to support the discovery of new drugs targeting NRs. NRLiSt BDB is freely available online at http://nrlist.drugdesign.fr .

[1]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[2]  I. McLay,et al.  Design and x-ray crystal structures of high-potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on the receptor , 2009, Proceedings of the National Academy of Sciences.

[3]  R Abagyan,et al.  Rational discovery of novel nuclear hormone receptor antagonists , 2000, Proc. Natl. Acad. Sci. USA.

[4]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[5]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[6]  Ajay N. Jain,et al.  Parameter estimation for scoring protein-ligand interactions using negative training data. , 2006, Journal of medicinal chemistry.

[7]  Hideki Matsui,et al.  Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists. , 2011, Journal of medicinal chemistry.

[8]  I. McLay,et al.  The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist. , 2008, Bioorganic & medicinal chemistry letters.

[9]  J. Takahashi,et al.  Regulation of Circadian Behavior and Metabolism by Synthetic REV-ERB Agonists , 2012, Nature.

[10]  Maria A Miteva,et al.  Structure‐based virtual ligand screening with LigandFit: Pose prediction and enrichment of compound collections , 2007, Proteins.

[11]  T. Willson,et al.  Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition , 2002, Cell.

[12]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[13]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[14]  Maria A Miteva,et al.  Fast structure-based virtual ligand screening combining FRED, DOCK, and Surflex. , 2005, Journal of medicinal chemistry.

[15]  Tudor I. Oprea,et al.  Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection? , 2008, J. Comput. Aided Mol. Des..

[16]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[17]  Ruben Abagyan,et al.  Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles , 2010, J. Comput. Aided Mol. Des..

[18]  Ning Zhang,et al.  NURBS: a database of experimental and predicted nuclear receptor binding sites of mouse , 2013, Bioinform..

[19]  D. Moras,et al.  Structure-activity relationship of nuclear receptor-ligand interactions. , 2003, Current topics in medicinal chemistry.

[20]  C. Glass,et al.  Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. , 2007, Trends in immunology.

[21]  R. Margolis,et al.  The Nuclear Receptor Signaling Atlas: development of a functional atlas of nuclear receptors. , 2005, Molecular endocrinology.

[22]  H. Xu,et al.  Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol , 2007, Molecular and Cellular Biology.

[23]  Joanna L Sharman,et al.  IUPHAR-DB: an open-access, expert-curated resource for receptor and ion channel research. , 2011, ACS chemical neuroscience.

[24]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[25]  H. Gronemeyer,et al.  Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. , 2000, Trends in pharmacological sciences.

[26]  B. Katzenellenbogen,et al.  Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. , 2000, Journal of medicinal chemistry.

[27]  S. Chong,et al.  Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[28]  D. Rognan,et al.  Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.

[29]  Jonathan Greer,et al.  The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain , 2003, Journal of Biological Chemistry.

[30]  Brian K. Shoichet,et al.  Rapid Context-Dependent Ligand Desolvation in Molecular Docking , 2010, J. Chem. Inf. Model..

[31]  Claudio N. Cavasotto,et al.  Ligand and Decoy Sets for Docking to G Protein-Coupled Receptors , 2012, J. Chem. Inf. Model..

[32]  A. Nicholls,et al.  How to do an evaluation: pitfalls and traps , 2008, J. Comput. Aided Mol. Des..

[33]  I. McLay,et al.  X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. , 2008, Journal of medicinal chemistry.

[34]  Matthieu Montes,et al.  Multiple Structures for Virtual Ligand Screening: Defining Binding Site Properties-Based Criteria to Optimize the Selection of the Query , 2013, J. Chem. Inf. Model..

[35]  Jun Qin,et al.  Minireview: Evolution of NURSA, the Nuclear Receptor Signaling Atlas. , 2009, Molecular endocrinology.

[36]  Paul Webb,et al.  Conformational adaptation of nuclear receptor ligand binding domains to agonists: Potential for novel approaches to ligand design , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[37]  B. Katzenellenbogen,et al.  Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. , 2001, Journal of medicinal chemistry.

[38]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[39]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[40]  Guy Perrière,et al.  Update of NUREBASE: nuclear hormone receptor functional genomics , 2004, Nucleic Acids Res..

[41]  John J. Irwin,et al.  Community benchmarks for virtual screening , 2008, J. Comput. Aided Mol. Des..

[42]  Bas Vroling,et al.  NucleaRDB: information system for nuclear receptors , 2011, Nucleic Acids Res..

[43]  Guy Perrière,et al.  NUREBASE: database of nuclear hormone receptors , 2002, Nucleic Acids Res..

[44]  J. Gasteiger,et al.  Automatic generation of 3D-atomic coordinates for organic molecules , 1990 .

[45]  Joost J. J. van Durme,et al.  NRMD: Nuclear Receptor Mutation Database , 2003, Nucleic Acids Res..

[46]  J. Prous,et al.  Experimental approaches to study PPAR gamma agonists as antidiabetic drugs. , 2002, Methods and findings in experimental and clinical pharmacology.

[47]  M. Makishima,et al.  Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands. , 2006, Bioorganic & medicinal chemistry letters.

[48]  Timothy M Willson,et al.  A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor*[boxs] , 2005, Journal of Biological Chemistry.